Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program

Got To Article
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for an additional commitment of up to $2.
0 comments